Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Research & Development (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Research & Development for 5 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 9.36% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.0 million through Dec 2025, up 8.33% year-over-year, with the annual reading at $58.0 million for FY2025, 8.33% up from the prior year.
  • Research & Development hit $14.8 million in Q4 2025 for Krystal Biotech, up from $14.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.6 million in Q2 2024 to a low of $6.1 million in Q3 2021.
  • Historically, Research & Development has averaged $11.4 million across 5 years, with a median of $11.4 million in 2022.
  • Biggest five-year swings in Research & Development: soared 89.41% in 2022 and later decreased 10.83% in 2024.
  • Year by year, Research & Development stood at $9.0 million in 2021, then rose by 19.23% to $10.7 million in 2022, then increased by 5.87% to $11.4 million in 2023, then grew by 18.96% to $13.5 million in 2024, then grew by 9.36% to $14.8 million in 2025.
  • Business Quant data shows Research & Development for KRYS at $14.8 million in Q4 2025, $14.6 million in Q3 2025, and $14.4 million in Q2 2025.